ImmuPharma, Avion ink Lupuzor deal
admin 28th November 2019 Uncategorised 0Avion is set to fund a new international Phase III trial with costs up to $25 million. More: ImmuPharma, Avion ink Lupuzor deal Source: News
read more
Avion is set to fund a new international Phase III trial with costs up to $25 million. More: ImmuPharma, Avion ink Lupuzor deal Source: News
read moreAs many as 3,200 women in England living with advanced HR+, HER2- breast cancer will now be eligible for the treatment. More: NICE approves Ibrance via Cancer Drugs Fund Source: News
read moreIn this week’s FiercePharmaPolitics, an analyst outlines how current drug pricing proposals would affect the industry, plus more. Some proposals would bring modest disruption to drug companies, but House speaker Nancy Pelosi’s plan would bring a “fundamental change of business
read moreWhen Insys founder John Kapoor was found guilty on federal racketeering charges in May, it marked the stiffest conviction yet for an opioid executive at the center of the nation’s addiction crisis. Now, a federal judge says prosecutors failed to present enough
read moreA 10% increase in vaccination may be associated with as much as a 10% fall in sickness absence. More: NHS encourages staff to lead ‘flu jab drive’ Source: News
read moreThe CGT Catapult has released its latest Good Manufacturing Practice report and skills demand report. More: New report shows growth in cell and gene therapy sector Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals